The mild approach is a minimally invasive procedure with a positive response rate of 81 percent in treated LSS patients, according to the release. The FDA cleared the procedure in 2008, and since then, 15,000 people have been treated.
Pitango Venture Capital led the recent financing round.
More Articles on Devices:
Aesculap Releases CeSpace Interbody ACDF System
SpineGuard Issued Patent for PediGuard Pedicle Screw With Built-In Sensor
Jury Sides with Depuy-Synthes in $16M Patent Infringement Ruling Against Globus
